<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-88698" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fludrocortisone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rahman</surname>
            <given-names>Masum</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anjum</surname>
            <given-names>Fatima</given-names>
          </name>
          <aff>Temple University, Lewis Katz School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Masum Rahman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Fatima Anjum declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-88698.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This activity&#x000a0;discusses&#x000a0;the synthetic adrenal steroid fludrocortisone, which possesses potent mineralocorticoid activity. Normally prescribed for adrenocortical insufficiency, its versatile off-label applications extend to managing orthostatic hypotension and postural orthostatic tachycardia syndrome. By exploring its mechanism of action, adverse event profile, and other critical aspects, including&#x000a0;dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions,&#x000a0;participants gain essential insights to administer fludrocortisone&#x000a0;for various indications adeptly. Understanding fludrocortisone's pharmacology empowers healthcare professionals to make informed therapeutic decisions and optimize patient care outcomes, particularly in adrenocortical insufficiency treatment. Equipping healthcare professionals with this practical guide enhances their capacity to navigate complex medical scenarios, elevating the standard of healthcare delivery and ultimately improving patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of fludrocortisone.</p></list-item><list-item><p>Evaluate&#x000a0;the potential adverse effects of fludrocortisone.</p></list-item><list-item><p>Determine&#x000a0;the need for appropriate monitoring strategies for patients who are receiving fludrocortisone.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from&#x000a0;fludrocortisone&#x000a0;treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=88698&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=88698">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-88698.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Fludrocortisone was granted a patent in 1953 and is on the World Health Organization's List of Essential Medicines.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Fludrocortisone is essential in treating primary and secondary adrenocortical insufficiency due to its potent mineralocorticoid effect.<xref ref-type="bibr" rid="article-88698.r1">[1]</xref>&#x000a0;This drug may also be used to treat congenital adrenal hyperplasia (CAH).<xref ref-type="bibr" rid="article-88698.r2">[2]</xref>&#x000a0;CAH is a congenital enzymatic deficiency disorder with mineralocorticoid deficiency in up to 75% of cases.&#x000a0;The Endocrine Society guidelines endorse fludrocortisone&#x000a0;for congenital adrenal hyperplasia due to 21-hydroxylase deficiency.<xref ref-type="bibr" rid="article-88698.r3">[3]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>According to ACC/AHA/HRS guidelines, fludrocortisone can be prescribed for syncope due to neurogenic orthostatic hypotension.&#x000a0;Fludrocortisone may be considered in cases of recurrent vasovagal syncope with an insufficient response to increased salt and water intake.<xref ref-type="bibr" rid="article-88698.r4">[4]</xref><xref ref-type="bibr" rid="article-88698.r5">[5]</xref>&#x000a0;The 2015 Heart Rhythm Society&#x000a0;guidelines endorses&#x000a0;fludrocortisone for&#x000a0;postural orthostatic tachycardia syndrome (POTS).<xref ref-type="bibr" rid="article-88698.r6">[6]</xref>&#x000a0;It has also been used in the management of septic shock in adults, demonstrating a 90-day all-cause mortality reduction among the group receiving hydrocortisone plus fludrocortisone than among those with a placebo.<xref ref-type="bibr" rid="article-88698.r7">[7]</xref><xref ref-type="bibr" rid="article-88698.r8">[8]</xref><xref ref-type="bibr" rid="article-88698.r9">[9]</xref><xref ref-type="bibr" rid="article-88698.r10">[10]</xref>&#x000a0;In a recent network meta-analysis of 17 randomized trials involving adult patients with septic shock, the combination of fludrocortisone plus hydrocortisone emerged as more effective in reducing all-cause mortality.<xref ref-type="bibr" rid="article-88698.r11">[11]</xref></p>
      </sec>
      <sec id="article-88698.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Fludrocortisone acetate is an inactive pro-drug requiring hydrolyzation by esterases or pseudo-esterases in the liver and other body fluids.<xref ref-type="bibr" rid="article-88698.r12">[12]</xref>&#x000a0;Fludrocortisone is a synthetic adrenal steroid with high mineralocorticoid activity and is practically devoid of glucocorticoid effect. As an analog, its mechanism of action and the permissive effects on &#x003b1;-adrenoreceptors are similar to the endogenous mineralocorticoid. High lipid solubility allows fludrocortisone to penetrate the plasma membrane easily and bind with its cytoplasmic receptor.</p>
        <p>Upon binding, the receptor complex translocates to the nucleus and initiates the transcription of responsive genes to exert its effects. The primary sites of fludrocortisone's effect are the distal convoluted tubules and collecting ducts, which enhance Na<sup>+</sup> and water retention and increase K<sup>+</sup> and H<sup>+</sup> excretion. This pharmacologic effect leads to a generalized ECF volume expansion not explicitly targeted to the intravascular space. Thus, it is postulated that its efficacy in orthostatic hypotension management is due to potentiating the pressor effects of various endogenous vasoconstrictors such as norepinephrine and angiotensin II.<xref ref-type="bibr" rid="article-88698.r13">[13]</xref></p>
        <p>
<bold>Pharmacokinetics&#x000a0;</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Fludrocortisone is well absorbed with a Tmax of 0.5 to 2 hours.</p>
        <p><bold>Distribution:</bold>&#x000a0;The apparent volume of distribution for fludrocortisone is substantial, ranging from 80 to 85 L, with minimal observed penetration into the cerebrospinal fluid.</p>
        <p><bold>Metabolism:</bold> As explained earlier, fludrocortisone acetate is an inactive pro-drug requiring hydrolyzation by esterases or pseudo-esterases in the liver.<xref ref-type="bibr" rid="article-88698.r12">[12]</xref>&#x000a0;The significant mineralocorticoid effects of fludrocortisone are due to the reduction in 11&#x003b2;-oxidation.</p>
        <p><bold>Elimination:</bold>&#x000a0;Approximately 80% of fludrocortisone is excreted in urine, while the remaining 20% is expected to be eliminated via feces or bile. Population pharmacokinetics estimate the plasma clearance of fludrocortisone to be around 40.8 L/h. Despite reported variations in plasma half-life, spanning from 1 to 3.5 hours, the provided prescribing information generally indicates an approximate half-life ranging from 18 to 36 hours for fludrocortisone.&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Fludrocortisone#section=Absorption-Distribution-and-Excretion">(Data adapted from PubChem)</ext-link></p>
      </sec>
      <sec id="article-88698.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths </bold>
</p>
        <p>Fludrocortisone acetate is available in tablet form, with each tablet containing 0.1 mg of the medication. Fludrocortisone can be taken orally with or without a meal.&#x000a0;</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Primary adrenal cortical insufficiency: The usual&#x000a0;dosage for primary adrenal cortical insufficiency is 0.1 mg daily, which can be increased to 0.2 mg daily. However, if hypertension develops, the dosage should be reduced to 0.05 mg per day. Dosing should be gradually tapered down to discontinue therapy.</p>
        <p>Congenital adrenal hyperplasia: The appropriate dose for salt-losing type congenital adrenal hyperplasia is 0.1 mg daily.</p>
        <p>Orthostatic hypotension: When used off-label for orthostatic hypotension, the&#x000a0;dosage is normally from 0.1 to 0.2 mg orally once daily. Dosing should start at 0.1 mg by mouth each day, then increase the dose by 0.1 mg per day each week until the appearance of trace pedal edema. The maximum&#x000a0;dosage is 1 mg daily, although doses over 0.5 mg are rarely more effective. Fludrocortisone should be administered with food or milk. Discontinuation of therapy requires gradual dose tapering.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0; There are no dosage adjustments for fludrocortisone provided in the&#x000a0;product labeling; use with caution.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;No dosage adjustments for fludrocortisone are provided in the&#x000a0;product labeling; use with caution due to the potential for&#x000a0;volume&#x000a0;overload.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Fludrocortisone is a category C pregnancy drug. Fludrocortisone acetate should only be given to a pregnant woman if absolutely necessary. Additionally, infants born to mothers who received substantial doses of fludrocortisone acetate during pregnancy should be carefully observed for signs of hypoadrenalism. According to the Heart Rhythm Society (HRS) guidelines 2023, syncope is common in pregnancy due to altered venous return and cardiac output; vasovagal syncope is most commonly encountered. Conservative measures, such as increasing salt and water intake and avoiding triggers, are first-line therapies. Increased salt intake and fludrocortisone may be helpful in refractory cases after the first trimester.<xref ref-type="bibr" rid="article-88698.r14">[14]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Corticosteroids are present in the breast milk of lactating women receiving systemic therapy. Caution is advised when administering fludrocortisone acetate to nursing women.</p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Fludrocortisone is&#x000a0;used off-label&#x000a0;for&#x000a0;cerebral salt wasting, characterized by inappropriate natriuresis and volume contraction in the presence of cerebral pathology. There have been reports of successful outcomes, underscoring its efficacy in managing this challenging condition.<xref ref-type="bibr" rid="article-88698.r15">[15]</xref>&#x000a0;A&#x000a0;retrospective study investigated the effectiveness of fludrocortisone in pediatric vasovagal syncope (VVS). Among 67 patients, those treated with fludrocortisone showed a significantly lower recurrence rate of syncopal events (39.3%) compared to the no-medication group (64.1%). Additionally, the fludrocortisone group exhibited a higher rate of negative change in the follow-up tilt-table test (57.1%) compared to the no-medication group (28.2%). These findings suggest that fludrocortisone may be more effective in pediatric VVS.<xref ref-type="bibr" rid="article-88698.r16">[16]</xref></p>
        <p><bold>Older patients:&#x000a0;</bold>In older adults, fludrocortisone therapy may exacerbate conditions such as hypertension, edema, hypokalemia, congestive heart failure, cataracts, glaucoma, increased intraocular pressure, renal insufficiency, and osteoporosis. Caution and close monitoring are advised, and dose adjustments are made as needed.</p>
      </sec>
      <sec id="article-88698.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Most of the&#x000a0;adverse effects of fludrocortisone are related to mineralocorticoid activity. If this drug is used along with glucocorticoid or other related drugs, the adverse effect increases. Some of the more common or significant&#x000a0;adverse&#x000a0;effects&#x000a0;appear in the list below:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cardiovascular system:&#x000a0;Hypertension (dose-dependent; has been described as an adverse effect on children using fludrocortisone for CAH, which correlates with plasma renin activity), fluid retention, and edema (may cause swelling of lower limbs), congestive heart failure.<xref ref-type="bibr" rid="article-88698.r17">[17]</xref><xref ref-type="bibr" rid="article-88698.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nervous System:&#x000a0;Headache, increased intracranial pressure, vertigo, change in behavior, convulsion</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal: Stomach ulcer and perforation; the gastric protective barrier is impaired</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Endocrine: Menstrual abnormalities, cushingoid features, growth delay in a child, acute adrenal insufficiency in times of stress</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Musculoskeletal: Muscle weakness, reduced muscle mass, increased risk of osteoporosis and pathological fracture, vertebral compression, necrosis of femoral head</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dermatologic: Increased sweating, poor wound healing, hirsutism, thinning of the skin, severe allergic reaction</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ophthalmic: Cataracts,&#x000a0;glaucoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Metabolic: Elevated blood and urine glucose, weight gain</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Electrolytes Disturbance:&#x000a0;Severe hypokalemia, metabolic alkalosis&#x000a0;<xref ref-type="bibr" rid="article-88698.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Antacids: Administration of fludrocortisone with proton pump inhibitors and&#x000a0;antacids&#x000a0;has been shown to decrease its absorption.<xref ref-type="bibr" rid="article-88698.r12">[12]</xref>&#x000a0;Concurrent use of amphotericin B, diuretics, and digoxin with fludrocortisone may cause severe hypokalemia.<xref ref-type="bibr" rid="article-88698.r20">[20]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>NSAIDS: Concurrent use of fludrocortisone with NSAIDs can&#x000a0;increase the risk of&#x000a0;peptic ulcer disease.<xref ref-type="bibr" rid="article-88698.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Warfarin: Fludrocortisone can alter the efficacy of&#x000a0;warfarin. Patients' PT/INR levels should be monitored.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Oral hypoglycemic agents:&#x000a0;Fludrocortisone can cause hyperglycemia, so dosages of diabetes drugs (metformin, glipizide, glimepiride, pioglitazone, linagliptin, insulin) must be adjusted.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Enzyme inducers: Administration of&#x000a0;phenobarbital, phenytoin, and rifampin&#x000a0;can lower blood fludrocortisone levels.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hormones: Taking estrogen or male testosterone analog with&#x000a0;fludrocortisone can increase the risk of swelling.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Vaccines: Fludrocortisone's immunosuppressive properties may compromise vaccine efficacy. Therefore, it is recommended that vaccines be avoided during fludrocortisone use.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-88698.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Fludrocortisone is contraindicated in several conditions. Clinicians should conduct a careful history and examination before prescribing this drug. If there is any contraindication to this drug, alternative options should be considered. Contraindications include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Known allergy to fludrocortisone or its excipients&#x000a0;<xref ref-type="bibr" rid="article-88698.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Systemic fungal infection</p>
          </list-item>
        </list>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinicians should prescribe fludrocortisone with caution in patients with hypertension or hypoalbuminemia.</p>
          </list-item>
          <list-item>
            <p>Fludrocortisone acetate is reserved for active tuberculosis cases requiring corticosteroid use in conjunction with antituberculous treatment. In latent tuberculosis or tuberculin reactivity, cautious monitoring is crucial, and chemoprophylaxis is recommended during prolonged corticosteroid therapy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-88698.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Since this drug can cause a life-threatening hypersensitivity reaction, the patient must be monitored for the development of any allergic sign symptoms such as rash, breathing problem, swelling of the face, or fever. Blood pressure should be recorded regularly while using this corticosteroid as it has been associated with iatrogenic hypertension. Serial plasma renin activity should also be checked. If there is weakness or muscle cramps,&#x000a0;serum electrolytes should be checked to identify and treat hypokalemia.<xref ref-type="bibr" rid="article-88698.r20">[20]</xref>&#x000a0;Monitoring serum blood glucose levels is essential to manage hyperglycemia during fludrocortisone therapy, especially in&#x000a0;patients with diabetes. If the drug is being&#x000a0;prescribed for a child for a longer duration, the growth and development of the child should be tracked to see if there is any delay in growth.</p>
      </sec>
      <sec id="article-88698.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>The toxicity of any drug depends on&#x000a0;its pharmacological activity. Since fludrocortisone works&#x000a0;on mineralocorticoid receptors, toxicity will present as excess mineralocorticoid activities such as severe hypertension, not pitting edema, congestive heart failure, severe hypokalemia, metabolic alkalosis, and rapid weight gain.<xref ref-type="bibr" rid="article-88698.r23">[23]</xref>&#x000a0;One case report describes a 41-year-old woman diagnosed with adrenal insufficiency who developed Takotsubo cardiomyopathy following the initiation of hormone replacement therapy with hydrocortisone and fludrocortisone (0.3 mg/day). Notably, her cardiac function significantly improved after a substantial reduction in fludrocortisone dosage to 0.05 mg/day.<xref ref-type="bibr" rid="article-88698.r23">[23]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There is no antidote for fludrocortisone toxicity, making conservative management the mainstay of treatment. Reduction of dose, strict blood pressure control, and potassium supplementation may be given.</p>
      </sec>
      <sec id="article-88698.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Fludrocortisone is used worldwide and prescribed by clinicians, osteopathic clinicians, physician assistants, and nurse practitioners.&#x000a0;Since fludrocortisone can interact with many other medications and may cause serious adverse effects or toxicity,&#x000a0;interprofessional healthcare team members must be knowledgeable of these consequences.&#x000a0;All team members, whether involved in prescribing, dispensing, administering, or monitoring fludrocortisone,&#x000a0;must be well-educated about the pharmacology of this drug. A proper history and physical examination must be considered before initiating fludrocortisone. The patient&#x000a0;should&#x000a0;be educated about the adverse effects, potential toxicity,&#x000a0;and appropriate dosing of this drug so they can use&#x000a0;the medication properly. Patients should inform their clinician of adverse reactions or symptoms for prompt evaluation and management. For congenital adrenal hyperplasia, consult an endocrinologist and a pediatrician for the best care.&#x000a0;Referral to a cardiologist may be required when considering fludrocortisone for&#x000a0;postural orthostatic tachycardia syndrome.</p>
        <p>Interprofessional team&#x000a0;discussion&#x000a0;that includes all clinicians (including specialists such as endocrinologists), nursing staff, and pharmacists&#x000a0;is crucial for every patient. The interprofessional team must monitor the patient regularly and be ready for a prompt response if there are any signs or symptoms of adverse events. Family members should also be educated about proper dosing, adverse effects, and warning signs. This team approach will drive improved patient outcomes and mitigate potential adverse events. An interprofessional team approach and open communication between clinicians (MDs, DOs, NPs, PAs), nurses, specialists, and pharmacists are necessary to&#x000a0;optimize patient outcomes with&#x000a0;fludrocortisone.</p>
      </sec>
      <sec id="article-88698.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=88698&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=88698">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/88698/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=88698">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-88698.s11">
        <title>References</title>
        <ref id="article-88698.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ceccato</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Torchio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tizianel</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Peleg Falb</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barbot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sabbadin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Betterle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Scaroni</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Renin and electrolytes indicate the mineralocorticoid activity of fludrocortisone: a 6&#x000a0;year study in primary adrenal insufficiency.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>111</fpage>
            <page-range>111-122</page-range>
            <pub-id pub-id-type="pmid">35947299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rowlands</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deeb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ladjouze</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamza</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Musa</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Raza</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jennane</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Abu-Libdeh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chanoine</surname>
                <given-names>JP</given-names>
              </name>
              <collab>GPED CAH Working Group</collab>
            </person-group>
            <article-title>Access to fludrocortisone and to hydrocortisone in children with congenital adrenal hyperplasia in the WHO Eastern Mediterranean Region: it takes a village&#x02026;.</article-title>
            <source>BMJ Glob Health</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">34675026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Speiser</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Arlt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Auchus</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Baskin</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Conway</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Merke</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Meyer-Bahlburg</surname>
                <given-names>HFL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Oberfield</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>103</volume>
            <issue>11</issue>
            <fpage>4043</fpage>
            <page-range>4043-4088</page-range>
            <pub-id pub-id-type="pmid">30272171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Sheldon</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Benditt</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Grubb</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Hamdan</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Krahn</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Olshansky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Raj</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Sorajja</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>Aug</month>
            <day>01</day>
            <volume>136</volume>
            <issue>5</issue>
            <fpage>e60</fpage>
            <page-range>e60-e122</page-range>
            <pub-id pub-id-type="pmid">28280231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peixoto</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and management of orthostatic hypotension: Limited data, limitless opportunity.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2022</year>
            <month>Jan</month>
            <day>04</day>
            <volume>89</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-45</page-range>
            <pub-id pub-id-type="pmid">34983800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheldon</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Grubb</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Olshansky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brignole</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raj</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Krahn</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Morillo</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sandroni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Friday</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Hachul</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Mayuga</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Moak</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Kanjwal</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope.</article-title>
            <source>Heart Rhythm</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>e41</fpage>
            <page-range>e41-63</page-range>
            <pub-id pub-id-type="pmid">25980576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benner</surname>
                <given-names>BJM</given-names>
              </name>
              <name>
                <surname>Alsma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Feelders</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Hyponatraemia and hyperpigmentation in primary adrenal insufficiency.</article-title>
            <source>BMJ Case Rep</source>
            <year>2019</year>
            <month>Mar</month>
            <day>07</day>
            <volume>12</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30850564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Annane</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Renault</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brun-Buisson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Megarbane</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Quenot</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Siami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cariou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Forceville</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Schwebel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Timsit</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Misset</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ali Benali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Colin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Souweine</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Asehnoune</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mercier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chimot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Charpentier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fran&#x000e7;ois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Boulain</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Petitpas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Constantin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dhonneur</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baudin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Combes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boh&#x000e9;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Loriferne</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Amathieu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Slama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leroy</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Capellier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dargent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hissem</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maxime</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bellissant</surname>
                <given-names>E</given-names>
              </name>
              <collab>CRICS-TRIGGERSEP Network</collab>
            </person-group>
            <article-title>Hydrocortisone plus Fludrocortisone for Adults with Septic Shock.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>378</volume>
            <issue>9</issue>
            <fpage>809</fpage>
            <page-range>809-818</page-range>
            <pub-id pub-id-type="pmid">29490185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomes</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Madureira</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mendonca</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Bachega</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Mineralocorticoid replacement during infancy for salt wasting congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</article-title>
            <source>Clinics (Sao Paulo)</source>
            <year>2013</year>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>147</fpage>
            <page-range>147-52</page-range>
            <pub-id pub-id-type="pmid">23525308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Wilton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lole</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>OP</given-names>
              </name>
            </person-group>
            <article-title>Continuing need for mineralocorticoid therapy in salt-losing congenital adrenal hyperplasia.</article-title>
            <source>Arch Dis Child</source>
            <year>1979</year>
            <month>May</month>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>350</fpage>
            <page-range>350-5</page-range>
            <pub-id pub-id-type="pmid">475410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teja</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Berube</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Schanock</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wunsch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Walkey</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of Fludrocortisone Plus Hydrocortisone versus Hydrocortisone Alone in Septic Shock: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2024</year>
            <month>May</month>
            <day>15</day>
            <volume>209</volume>
            <issue>10</issue>
            <fpage>1219</fpage>
            <page-range>1219-1228</page-range>
            <pub-id pub-id-type="pmid">38271488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamitouche</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ribot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Polito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laviolle</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bellissant</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Annane</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of oral fludrocortisone in septic shock.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>82</volume>
            <issue>6</issue>
            <fpage>1509</fpage>
            <page-range>1509-1516</page-range>
            <pub-id pub-id-type="pmid">27416887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bamberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>William-Olsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Jansson-L&#x000f6;fmark</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hartleib-Geschwindner</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone.</article-title>
            <source>J Renin Angiotensin Aldosterone Syst</source>
            <year>2019</year>
            <season>Jan-Mar</season>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>1470320319827449</fpage>
            <pub-id pub-id-type="pmid">30813831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kapa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saarel</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Dubin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gorenek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hameed</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Lara de Melo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leal</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mond&#x000e9;sert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pacheco</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sarkozy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silversides</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Spears</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Srinivas</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Strasburger</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Tedrow</surname>
                <given-names>UB</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Zelop</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Zentner</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>2023 HRS expert consensus statement on the management of arrhythmias during pregnancy.</article-title>
            <source>Heart Rhythm</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>e175</fpage>
            <page-range>e175-e264</page-range>
            <pub-id pub-id-type="pmid">37211147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taplin</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Cowell</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Silink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ambler</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Fludrocortisone therapy in cerebral salt wasting.</article-title>
            <source>Pediatrics</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>118</volume>
            <issue>6</issue>
            <fpage>e1904</fpage>
            <page-range>e1904-8</page-range>
            <pub-id pub-id-type="pmid">17101713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Fludrocortisone in Pediatric Vasovagal Syncope: A Retrospective, Single-Center Observational Study.</article-title>
            <source>J Clin Neurol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <page-range>46-51</page-range>
            <pub-id pub-id-type="pmid">33480198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhattacharyya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tymms</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Heart failure with fludrocortisone in Addison's disease.</article-title>
            <source>J R Soc Med</source>
            <year>1998</year>
            <month>Aug</month>
            <volume>91</volume>
            <issue>8</issue>
            <fpage>433</fpage>
            <page-range>433-4</page-range>
            <pub-id pub-id-type="pmid">9816363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willis</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Byrne</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Fludrocortisone induced heart failure in Addison's disease.</article-title>
            <source>J Paediatr Child Health</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>280</fpage>
            <page-range>280-1</page-range>
            <pub-id pub-id-type="pmid">8074919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burns</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Semple</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Extreme metabolic alkalosis with fludrocortisone therapy.</article-title>
            <source>Postgrad Med J</source>
            <year>1983</year>
            <month>Aug</month>
            <volume>59</volume>
            <issue>694</issue>
            <fpage>506</fpage>
            <page-range>506-7</page-range>
            <pub-id pub-id-type="pmid">6622340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veltri</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Medication-induced hypokalemia.</article-title>
            <source>P T</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>185</fpage>
            <page-range>185-90</page-range>
            <pub-id pub-id-type="pmid">25798039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harris</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Raisch</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Abhyankar</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Marfatia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Sather</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs.</article-title>
            <source>Ann Pharmacother</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>1924</fpage>
            <page-range>1924-31</page-range>
            <pub-id pub-id-type="pmid">17047140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kato</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kamo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanikawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iketani</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity to fludrocortisone acetate in a recipient of bone marrow transplantation.</article-title>
            <source>Allergol Int</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>557</fpage>
            <page-range>557-8</page-range>
            <pub-id pub-id-type="pmid">21681020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-88698.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campean</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hasun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>St&#x000f6;llberger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bucher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Finsterer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schnack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weidinger</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison's disease: a case report.</article-title>
            <source>J Med Case Rep</source>
            <year>2016</year>
            <month>Oct</month>
            <day>12</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>281</fpage>
            <pub-id pub-id-type="pmid">27729057</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
